No Data
No Data
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test
Qiagen (QGE2.VI, QIA.F) and US-based genetic testing company Myriad Genetics (MYD.F) plan to jointly develop a globally distributable kit-based test for analyzing homologous recombination deficiency s
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test
Qiagen (QGEN) and Myriad Genetics (MYGN) said Thursday they are working to develop a portable kit-based test for analyzing cancer patients' Homologous Recombination Deficiency status. The test will co
Express News | Qiagen and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications
Express News | Myriad Genetics Inc:
QIAGEN And Myriad Genetics To Develop Globally Distributable Kit-Based Test For Analyzing Homologous Recombination Deficiency (HRD) Status
QIAGEN And Myriad Genetics To Develop Globally Distributable Kit-Based Test For Analyzing Homologous Recombination Deficiency (HRD) Status
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO Annual Meeting
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO
Jaguar8 : Yes it’s quite disappointing that people don’t realize the importance of this.
TrytosaveabitOP Jaguar8: Yup! I have a volume and price move alerts set! Hehehe
Jaguar8 TrytosaveabitOP: What volume do you usually set like 1M?
TrytosaveabitOP Jaguar8: 300K in 3 minutes
Jaguar8 TrytosaveabitOP: Wow that is fast volume
View more comments...